Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Type
Public
HQ
Rockville, US
Founded
1996
Size (employees)
139 (est)
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US
Report incorrect company information

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Chiyoda, JP
NBF Hibiya Building, 10th Floor 1-1-7 Uchisaiwaicho
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6-7-6 Minatojima Minamimachi, Chuo-ku, Kobe City
Kita Ward, JP
Nishiumeda MID Building, 4th Floor 2-2-16 Sonezakishinchi
Sanda-shi, JP
4-1 Techno-Park
Zug, CH
22 Baarerstrasse
Show all (7)
Report incorrect company information

Sucampo Pharmaceuticals Financials and Metrics

Sucampo Pharmaceuticals Financials

Sucampo Pharmaceuticals's revenue was reported to be $230.06 m in FY, 2016 which is a 50.2% increase from the previous period.
USD

Revenue (Q3, 2017)

61.3 m

Gross profit (Q3, 2017)

43.8 m

Gross profit margin (Q3, 2017), %

71.5%

Net income (Q3, 2017)

10.4 m

EBIT (Q3, 2017)

21.2 m

Market capitalization (13-Feb-2018)

1.2 b

Cash (30-Sep-2017)

75 m
Sucampo Pharmaceuticals's current market capitalization is $1.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

89.6 m115.5 m153.2 m230.1 m

Revenue growth, %

29%33%50%

Cost of goods sold

12.4 m16.3 m36.7 m76 m

Gross profit

77.2 m99.2 m116.4 m154.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

21.2 m22.2 m24.1 m31.5 m29.5 m34.9 m33.4 m47.2 m52 m57.9 m56.3 m59.9 m61.3 m

Cost of goods sold

6.3 m3.5 m3.8 m5 m6.1 m7.3 m5.3 m23.3 m20.4 m15.6 m16.9 m17 m17.4 m

Gross profit

14.9 m18.6 m20.3 m26.5 m23.4 m27.6 m28.2 m23.9 m31.6 m42.3 m39.4 m42.9 m43.8 m

Gross profit Margin, %

70%84%84%84%79%79%84%51%61%73%70%72%72%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.1 m71.6 m108.3 m198.3 m

Accounts Receivable

5.4 m5.3 m22.8 m43 m

Inventories

4 m3.4 m8.9 m23.5 m

Current Assets

113.4 m122.3 m251.4 m307.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

39.9 m56.1 m53.5 m56.1 m59.6 m71.3 m91.5 m130.1 m128 m128.5 m243.5 m84.7 m75 m

Accounts Receivable

2.7 m4.4 m4.8 m8.5 m8.2 m8.2 m6.7 m16.1 m18.2 m20.7 m20.5 m19.8 m33.1 m

Inventories

261 k455 k423 k133 k328 k308 k296 k24.4 m21.6 m24.2 m23 m23.1 m34.7 m

Current Assets

105.7 m122.6 m119.3 m124.1 m120.9 m136.7 m161.4 m228.1 m237.7 m237.5 m322.4 m165.1 m190.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.4 m13.1 m33.4 m18.5 m

Depreciation and Amortization

1.5 m10.6 m45.7 m

Inventories

(163 k)(1.4 m)(1.2 m)

Accounts Payable

2.2 m(1.7 m)(2.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

1.3 m675 k1.6 m1.5 m6.4 m9.6 m7.2 m(4.1 m)(832 k)8.1 m4.6 m10.4 m

Inventories

423 k133 k328 k308 k296 k24.4 m21.6 m24.2 m34.7 m

Accounts Payable

5.6 m5.9 m1.4 m3.9 m4.9 m5.1 m6.2 m7.9 m8 m6.2 m
USDY, 2017

Revenue/Employee

440.8 k

Financial Leverage

9.8 x
Show all financial metrics
Report incorrect company information

Sucampo Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information